News
Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback